People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ...